NCT04632758进行中（未招募）3 期
An Open-label, Randomized, Multicenter Phase 3 Study Comparing WX-0593 to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 292
- 试验地点
- 1
- 主要终点
- Progression-free Survival (PFS)
研究概览
简要总结
The primary purpose of this study is to evaluate the efficacy and safety of WX-0593 vs. crizotinib in patients with ALK-positive non-small cell lung cancer who had not received prior systemic therapy
详细描述
To evaluate the efficacy and safety of WX-0593 vs. crizotinib in patients with ALK-positive NSCLC who had not received prior systemic therapy, to obtain additional pharmacokinetic (PK) data from sparse PK sampling, to compare the quality of life (QoL) in patients receiving WX-0593 vs. crizotinib, to evaluate the status of exploratory biomarkers and correlate with clinical outcome, and to obtain germline DNA samples for possible pharmacogenetic analysis in the event that outliers with respect to efficacy, tolerability/safety, or exposure are identified.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Female or male
- •Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤
- •Life expectancy of at least 12 weeks.
- •At least one measurable lesion (according to RECIST v1.1)
- •Histologically or cytologically confirmed diagnosis of advanced or recurrent or metastatic NSCLC that is ALK-positive by an Abbott FISH assay in the central lab. Randomization will occur after ALK positive confirmation is received from the central lab or local test using an method including Abbott FISH、RT-PCR or Ventana IHC.
- •No brain metastasis, or asymptomatic brain metastasis, or symptomatic brain metastasis but stable for more than 4 weeks after treatment, and have stopped systemic hormone treatment (prednisone of > 10 mg/day or equivalent hormone) for more than 2 weeks
- •Patients must have normal function as defined: ANC≥1.5*10^9/L; PLT≥90*10^9/L, Hb≥90 g/L, Total Bilirubin （TBIL）≤1.5*Upper Limit of Normal（ULN） ( Gilbert's Syndrome TBIL ≤3.0*ULN and DBIL≤1.5*ULN )，Alanine Transaminase （ALT）and Aspartate Aminotransferase（AST）≤2.5*ULN. For liver metastasis patients, ALT and AST≤5*ULN, Cr≤1.5*ULN, LVEF≥50%.
- •Any surgery or prior radiation (expect for palliative radiation) /operations must have been completed at least 4 weeks prior to first dosing. Palliative radiation must have been completed at least 48 hours prior to first dosing.
- •Patients must be able to understand and volunteer to sign the informed consent.
排除标准
- •Patients that have previously received cancer therapy (i.e., other targeted therapies, chemotherapy, immunotherapy, biologic therapy, hormonal therapy).
- •Patients with tumor meningeal metastasis
- •Clinically significant cardiovascular disease within 6 months prior to first dosing.
- •Two consecutive corrected QT interval (QTc) > 480 ms through ECG examination during screening, ≥2 arrhythmias, ≥2 heart failure (according to CTCAE 4.03), atrial fibrillation and ventricular fibrillation of any grade, or clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention
- •Patients need medications that may prolong QT interval or induce torsades de pointes within 14 days prior to the first dosing or during the study.
- •Continuous use of corticosteroids for more than 30 days, or require chronic use of corticosteroids or other immunosuppressants
- •Past history of a large area of diffuse/interstitial pulmonary fibrosis, or known history of Grade 3 or 4 interstitial pulmonary fibrosis or interstitial lung disease.
- •Patients with Grade > 1 nausea, vomiting, or diarrhea (CTCAE 4.03), other GI dysfunction or GI disease that may potentially affect drug absorption.
- •Patients at risk for GI perforation or intestinal obstruction
- •Patient has received other investigational drug within 1 month prior to first dosing. Subject received other clinical trial treatment within 1 month prior to the first dose of the investigational drug.
- •Patients who are HBsAg-positive and/or HBcAB positive and HBV DNA > 103copies/mL, or HCV antibody-positive, or syphilis antibody- positive or known HIV infected.
- •Patients who cannot suspend the use of a strong CYP3A4 inducer or inhibitor at least 1 weeks prior to this study and during the study.
- •Patients who cannot suspend the use of a CYP3A4 substrate at least 1 weeks prior to this study and during the study, and the therapeutic index is low.
- •Females who are pregnant or breastfeeding. Pregnant or lactating female patients or a positive pregnancy test at baseline for females of childbearing potential.
- •Female patients who are unwilling to use effective contraceptive measures during the entire course of the study and within 6 months after the end of the study, or male patients who plan to have children.
- •Concurrent diseases that may seriously affect patient safety or impact patient completion of the study as determined by the investigator (such as clinically uncontrolled hypertension (blood pressure > 160/110 mmHg), severe diabetes, or thyroid disease).
- •Drug abusers and alcoholics. Drug or alcohol abuse. Alcohol abuse refers to drinking 14 units of alcohol per week: 1 unit = 285mL of beer, or 25mL of spirits, or 100mL of wine;
- •History of definitive neurological or mental disorder, including epilepsy or dementia
- •Patients with other malignant tumors within 5 years prior to screening (except for cured basal cell carcinoma of the skin, cervical carcinoma in situ, thyroid carcinoma in situ, and papillary thyroid carcinoma).
- •Patients with added risks associated with the study or may interfere with the interpretation of study results as determined by the investigator, or deemed unsuitable by the investigator and/or sponsor.
研究组 & 干预措施
WX-0593 Tablets
Experimental
Eligible patients with ALK+ NSCLC will receive WX-0593 tablets without food until documented disease progression or unacceptable toxicity. 60 mg of WX-0593 tablets, once daily for 7 days, followed by 180 mg of WX-0593 tablets, once daily in a 28-days cycle.
干预措施: WX-0593 Tablets (Drug)
crizotinib
Active Comparator
Eligible patients with ALK+ NSCLC will receive oral crizotinib at 250mg BID without food until documented disease progression or unacceptable toxicity.
干预措施: crizotinib (Drug)
结局指标
主要结局
Progression-free Survival (PFS)
时间窗: from randomization until firstly recorded disease progression or death (whichever occurs earlier), or to the date that the last patients observed for 12 months
PFS as assessed by independent radiology review based on RECIST v. 1.1 criteria
次要结局
- Confirmed Objective Response Rate (ORR) Assessed By independent radiology review(From fist administration to the date that the last patients observed for 12 months)
- Confirmed Objective Response Rate (ORR) Assessed By Investigators(From fist administration to the date that the last patients observed for 12 months)
- Time to Response (TTR) Assessed By Investigators(From fist administration to the date that the last patients observed for 12 months)
- Progression-free survival (PFS)(from randomization until firstly recorded disease progression or death (whichever occurs earlier), or to the date that the last patients observed for 12 months)
- OS(from randomization until death due to any cause, withdraws informed consent, is lost to follow-up or refuses phone visits, or study completion（up to 2.5 years）)
- Duration of response (DOR) Assessed By Investigators(From fist administration to the date that the last patients observed for 12 months)
- Time to CNS progression(From fist administration to the date that the last patients observed for 12 months)
- Patient reported time to deterioration (TTD)(From fist administration to the date that the last patients observed for 12 months)
- Time to Response (TTR) Assessed By independent radiology(From fist administration to the date that the last patients observed for 12 months)
- Duration of response (DOR) Assessed By independent radiology(From fist administration to the date that the last patients observed for 12 months)
- CNS response rate based on independent radiology review(From fist administration to the date that the last patients observed for 12 months)
- CNS response rate based on investigator assessment(From fist administration to the date that the last patients observed for 12 months)
- Patient reported health-related quality of life (HRQoL)(From fist administration to the date that the last patients observed for 12 months)
- Percentage of patients with adverse events(from the signing of the informed consent form until at least 28 days after the last dose of study drug was administered.)
- Plasma concentrations (Cssmin)(Cssmin before dosing on Cycle 1 Day 1, Cycle 1 Day 7, Cycle 1 Day 21, Cycle 2 Day 21, and Cycle 4 Day 21)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM PatientsT2DMType 2 Diabetes MellitusNCT05680155Hangzhou Sciwind Biosciences Co., Ltd.211
已完成
3 期
A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or ObesityWeight ManagementNCT05813795Hangzhou Sciwind Biosciences Co., Ltd.664
进行中（未招募）
3 期
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsNon-small Cell Lung CancerNCT02767804Xcovery Holdings, Inc.290
已完成
3 期
A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer PatientsNSCLC (Non-small Cell Lung Cancer)NCT01639001Pfizer207
进行中（未招募）
2 期
Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsNon-small Cell Lung CancerNCT05801107Qilu Pharmaceutical Co., Ltd.30